ArticleJournal of virology1991
Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120.
Article in Journal of virology, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 142 citations in OpenAlex.
- Potential of polylactic-co-glycolic acid (PLGA) for delivery Jembrana disease DNA vaccine Model (pEGFP-C1-tat).Journal of veterinary science · 2021Article
- Molecular characterization of the env gene from Brazilian field isolates of Bovine leukemia virus.Virus genes · 2007Article
- Evolution of broad host range in retroviruses leads to cell death mediated by highly cytopathic variants.Journal of virology · 2006Article
- Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant.Retrovirology · 2005Article
- Bystander killing during avian leukosis virus subgroup B infection requires TVB(S3) signaling.Journal of virology · 2003Article
- A naturally occurring substitution in human immunodeficiency virus Tat increases expression of the viral genome.Journal of virology · 2003Article
- HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades.Journal of virology · 2001Article
- Use of helper-free replication-defective simian immunodeficiency virus-based vectors to study macrophage and T tropism: evidence for distinct levels of restriction in primary macrophages and a T-cell line.Journal of virology · 2001Article
- Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection.Journal of virology · 2000Article
- Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.Journal of virology · 2000Article
- Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication.Journal of virology · 2000Article
- Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.Journal of virology · 1999Article
- Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.Journal of virology · 1999Article
- Coreceptor specificity of temporal variants of simian immunodeficiency virus Mne.Journal of virology · 1999Article
- A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques.Journal of virology · 1998Article
- Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.Journal of virology · 1998Article
- Exposure to bacterial products renders macrophages highly susceptible to T-tropic HIV-1.The Journal of clinical investigation · 1998Article
- beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE).Journal of virology · 1997Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Human immunodeficiency virus type 1 (HIV-1) isolates display differences in a variety of in vitro biological properties, including the ability to infect different cell types, the kinetics of replication, and cytopathicity in the infected cells. Studies with isolates obtained from the same individual over time have shown that these in vitro properties of the viral isolates correlate with pathogenicity in the host. The later isolates, recovered when disease has developed, display a wider cellular host range, replicate rapidly and to high titers in the infected cells, and induce syncytia in these cells. In the present studies, the genomic determinants of these biological properties were defined with recombinant viruses generated between two HIV-1 isolates recovered sequentially from the same individual. The results show that the rate of HIV-1 replication in the HUT 78 T-cell line is controlled by the first coding exon of tat. Infection of T-cell and monocytic cell lines is determined by two specific regions in the envelope gp120, one of which also confers the ability of an isolate to induce syncytia. Amino acid sequence comparison of the regions identified revealed minor differences between the two viral isolates: 2 amino acids in the tat gene product and 10 and 12 amino acids in the two regions of envelope gp120. These data suggest that small changes in the tat and env proteins can have dramatic effects on the pathogenic potential of HIV-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.